文献速递乳腺癌支持与姑息治疗

联合阻断TIGIT与抑制MDSC通过激活抗肿瘤免疫阻碍乳腺癌骨转移

Combining TIGIT Blockade with MDSC Inhibition Hinders Breast Cancer Bone Metastasis by Activating Antitumor Immunity.
PubMed 文献 · Cancer Discov · 2024-01-01

该研究利用免疫健全的自发性乳腺癌骨转移小鼠模型,在不同转移阶段对骨转移灶和外周骨髓进行免疫转录组分析,发现粒细胞与T细胞间的交互塑造免疫抑制微环境,PD-1/TIGIT信号轴和IL1β在其中起核心作用。靶向这些通路可减弱骨转移并改善生存。患者样本分析显示TIGIT和IL1β在人类骨转移中突出,提示联合靶向免疫抑制性粒细胞和功能失调T细胞可能是抑制骨转移的有前景的新治疗策略。

要点

  • 骨转移灶和外周骨髓免疫转录组随转移阶段动态变化
  • 粒细胞与T细胞交互塑造免疫抑制微环境
  • 联合靶向TIGIT和IL1β可减弱骨转移并改善生存

核心结论

  • 联合靶向免疫抑制性粒细胞和功能失调T细胞可能是抑制乳腺癌骨转移的有前景的新治疗策略。

研究设计与样本

  • 利用免疫健全的自发性乳腺癌骨转移小鼠模型,对骨转移灶和外周骨髓在不同转移阶段进行免疫转录组分析,并分析患者样本。

主要发现

  • 骨转移灶和外周骨髓的免疫转录组在转移过程中呈现动态变化。
  • 粒细胞与T细胞之间的交互是塑造免疫抑制微环境的核心。
  • PD-1和TIGIT信号轴及促炎细胞因子IL1β是粒细胞与T细胞交互的核心分子。
  • 体内靶向这些通路可减弱骨转移并改善生存。
  • 患者样本分析显示TIGIT和IL1β在人类骨转移中突出。

临床怎么用

  • 作者认为,联合靶向免疫抑制性粒细胞和功能失调T细胞可能是抑制骨转移的有前景的新治疗策略。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bone is the most common site of breast cancer metastasis. Bone metastasis is incurable and is associated with severe morbidity. Utilizing an immunocompetent mouse model of spontaneous breast cancer bone metastasis, we profiled the immune transcriptome of bone metastatic lesions and peripheral bone marrow at distinct metastatic stages, revealing dynamic changes during the metastatic process. We show that cross-talk between granulocytes and T cells is central to shaping an immunosuppressive microenvironment. Specifically, we identified the PD-1 and TIGIT signaling axes and the proinflammatory cytokine IL1β as central players in the interactions between granulocytes and T cells. Targeting these pathways in vivo resulted in attenuated bone metastasis and improved survival, by reactivating antitumor immunity. Analysis of patient samples revealed that TIGIT and IL1β are prominent in human bone metastasis. Our findings suggest that cotargeting immunosuppressive granulocytes and dysfunctional T cells may be a promising novel therapeutic strategy to inhibit bone metastasis. Significance: Temporal transcriptome profiling of the immune microenvironment in breast cancer bone metastasis revealed key communication pathways between dysfunctional T cells and myeloid derived suppressor cells. Cotargeting of TIGIT and IL1β inhibited bone metastasis and improved survival. Validation in patient data implicated these targets as a novel promising approach to treat human bone metastasis.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Monteran L, Ershaid N, Scharff Y, et al. Combining TIGIT Blockade with MDSC Inhibition Hinders Breast Cancer Bone Metastasis by Activating Antitumor Immunity. Cancer Discov. 2024. PMID: 38427556. doi:10.1158/2159-8290.CD-23-0762

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。